Compare Amphastar Pharmaceuticals Inc (AMPH) vs Bank of America Corp (BAC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Bank of America Corp — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Bank of America Corp trades at $59.8 (market cap $423.45B). The key difference: Bank of America Corp is far larger — about 512.6× Amphastar Pharmaceuticals Inc's market cap, and Bank of America Corp pays a 1.88% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | BAC | |
|---|---|---|
Market Cap | $826.08M | $423.45B |
Sector | Health | Financials |
52-Week High | $30.81 | $59.90 |
52-Week Low | $16.87 | $44.92 |
Enterprise Value | $1.22B | — |
Volume | — | 55,637,172 |
Dividend Yield | — | 1.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Bank of America (BAC) trades at $59.67, up 0.71% today, with a bullish technical signal and strong analyst consensus. Recent earnings beats and revenue growth to $113.1B in 2025 highlight fundamental strength. The stock is supported by a $2T+ deposit base and positive sentiment from media coverage of its strategic initiatives, including partnerships and hiring.
Outlook remains positive with a $63.79 consensus price target, though risks include volatile cash flows and regulatory scrutiny. Investment appeal lies in earnings momentum and potential capital returns post-stress tests, balanced by macroeconomic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Bank of America Corp
Bank of America Corporation operates as a financial holding company. The Company offers saving accounts, deposits, mortgage and construction loans, cash and wealth management, certificates of deposit, investment funds, credit and debit cards, insurance, mobile, and online banking services. Bank of America serves customers worldwide.
Read more on BAC →
